Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck KGaA has announced that its US affiliate, EMD Serono, received FDA approval of easypod, a delivery system for the administration of Saizen, a treatment for growth hormone deficiency.
Subscribe to our email newsletter
The device was designed to help patients administer a subcutaneous daily injection reliably and in just three steps.
A key feature of easypod is preset dosing, which means that patients no longer have to set their dose every day. It also tracks the number of doses administered, allowing physicians to monitor patient adherence to therapy.
Fereydoun Firouz, CEO and president of EMD Serono, said: “In today’s high-technology world, it is necessary to continue to innovate by developing delivery systems with easy-to-use settings and real-time data that empower patients and healthcare professionals to help improve patient care. easypod is an example of our commitment to breakthrough thinking and technology designed to answer unmet patient and caregiver needs.”